Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
Public ClinicalTrials.gov record NCT02541565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
Study identification
- NCT ID
- NCT02541565
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Composite Lymphoma
- Grade 3b Follicular Lymphoma
- Stage I Diffuse Large B-Cell Lymphoma
- Stage I Follicular Lymphoma
- Stage II Diffuse Large B-Cell Lymphoma
- Stage II Follicular Lymphoma
- Stage III Diffuse Large B-Cell Lymphoma
- Stage III Follicular Lymphoma
- Stage IV Diffuse Large B-Cell Lymphoma
- Stage IV Follicular Lymphoma
Interventions
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
- Prednisone Drug
- Rituximab Biological
- Vincristine Sulfate Drug
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2015
- Primary completion
- Dec 17, 2018
- Completion
- Dec 17, 2018
- Last update posted
- Oct 13, 2020
2015 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02541565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2020 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02541565 live on ClinicalTrials.gov.